Sunshine Biopharma Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by Sunshine Biopharma Inc. on May 27, 2015. The company is incorporated in Colorado with principal executive offices in Montreal, Quebec, Canada. The report details significant corporate governance changes regarding the issuance of unregistered equity securities and amendments to the Articles of Incorporation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on capital structure changes rather than operational financial performance.
Material Changes
- Unregistered Sale of Equity: The Board authorized the issuance of 500,000 shares of Series B Preferred Stock to Dr. Steve N. Slilaty (CEO, President, and Chairman).
- Voting Control: Each Series B share carries 1,000 votes. Consequently, Dr. Slilaty now controls approximately 85% of the eligible votes (530,702,067 out of 622,652,271).
- Articles of Incorporation Amendment: The company established a new class of Series B Preferred Stock with a stated value of $0.10 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. The primary risk disclosed is the significant concentration of voting power held by the CEO following this issuance. The Series B Preferred Stock is subordinated to Series A Preferred Stock but superior to all other classes upon liquidation. Holders are entitled to dividends only if declared by the Board, and there are no redemption rights.
Investor Verification Checklist
- Verify the total outstanding share count and the specific voting rights of existing Series A Preferred Stock.
- Confirm the impact of the 85% voting concentration on future corporate governance decisions.
- Review the attached Exhibit 3.5 (Amendment to Articles of Incorporation) for full legal terms of the Series B Preferred Stock.
- Check for any subsequent filings regarding the actual payment or conversion of these shares.